2d illustrations and photos
CG Oncology (CGON) has initiated steps to raise approximately $100M through an initial public offering.
Without specifying any terms in its SEC filing, the biotech company has shown interest in raising around $100M. However, this number is likely a placeholder and subject to change.
The company aims to list its shares on Nasdaq under the symbol CGON, with Morgan Stanley, Goldman Sachs, Cantor, and LifeSci Capital acting as underwriters.
Based in California, CG Oncology is focused on developing a bladder-sparing therapy for patients with bladder cancer, with its lead drug candidate, cretostimogene, currently in Phase 3 testing.
